Animal-grade in vivo siRNA is made using industry-leading synthesis platforms, methods and product quality control systems. Through special chemical modification methods, it has the advantages of high efficiency, specificity, stability and low toxicity. It can be directly injected into the body of animals to achieve systemic or local administration. in vivo siRNA can achieve excellent in vivo RNAi efficacy and related research. It is widely used in the research of key gene targets of animal disease models, such as treating diseases by inhibiting the expression of pathogenic genes.

BiOligo uses unique siRNA chemical modification technology and high-quality raw materials, and through a strict quality inspection control system, effectively enhances the stability of in vivo siRNA. Under the condition of good siRNA serum stability, maintain the high activity of siRNA, reduce immunogenicity, and minimize the toxicity of siRNA to experimental animals, meet the requirements of administration, and effectively improve the bioavailability of in vivo siRNA.

Advantages

1. Precise sequence design, effectively improve silencing efficiency and reduce off-target effects;

2. Special chemical modification, effectively increase stability and reduce immunogenicity;

3. Special labeling increases in vivo utilization and achieves targeted delivery;

4. Strict process control, removal of organic matter, inorganic matter, and potential endotoxins, etc.;

5. Large synthesis specification, high throughput, and multiple sequences g-level synthesis can be achieved in the same batch;

6. Each batch can be traced back to quality and provide complete quality documents.

Application

1. Preclinical in vivo RNAi drug target development validation;

2. RNAi drug in vivo distribution and metabolism studies;

3. RNAi drug in vivo toxicity studies.